Suppr超能文献

异常沙疗综合征及其独特蒙药处方的机制见解和生物标志物发现的差异综合组学分析。

Differential integrative omic analysis for mechanism insights and biomarker discovery of abnormal Savda syndrome and its unique Munziq prescription.

机构信息

Shenzhen Hospital of Southern Medical University, Shenzhen 518110, PR China.

Xinjiang Key Laboratory of Molecular Biology and Endemic Diseases, Xinjiang Medical University, Urumqi 830011,PR China.

出版信息

Sci Rep. 2016 Jun 14;6:27831. doi: 10.1038/srep27831.

Abstract

Research has shown that many cancers have acommon pathophysiological origin and often present with similar symptoms. In terms of Traditional Uighur Medicine (TUM) Hilit (body fluid) theory, abnormal Savda syndrome (ASS) formed by abnormal Hilit is the common phenotype of complex diseases and in particular tumours. Abnormal Savda Munziq (ASMq), one representative of TUM, has been effective in the treatment of cancer since ancient times. Despite the physiopathology of ASS, the relationship between causative factors and the molecular mechanism of ASMq are not fully understood. The current study expanded upon earlier work by integrating traditional diagnostic approaches with others utilizing systems biology technology for the analysis of proteomic (iTRAQ) and metabolomic ((1)H-NMR) profiles of Uighur Medicine target organ lesion (liver) tumours. The candidate proteins were analyzed by enrichment analysis of the biological process and biomarker filters. Subsequently, 3Omics web-based tools were used to determine the relationships between proteins and appropriate metabolites. ELISA assay and IHC methods were used to verify the proteomic result; the protein von Willebrand factor (vWF) may be the "therapeutic window" of ASMq and biomarkers of ASS. This study is likely to be of great significance for the standardization and modernization of TUM.

摘要

研究表明,许多癌症具有共同的病理生理学起源,常常表现出相似的症状。在传统维吾尔医学(TUM)体液理论中,由异常体液形成的异常沙维德综合征(ASS)是复杂疾病特别是肿瘤的共同表型。异常沙维德蒙齐克(ASMq)是 TUM 的代表之一,自古以来在癌症治疗中就有疗效。尽管 ASS 的病理生理学已经得到了研究,但导致因素与 ASMq 的分子机制之间的关系尚不完全清楚。本研究通过将传统诊断方法与利用系统生物学技术分析维吾尔医学靶器官病变(肝脏)肿瘤的蛋白质组学(iTRAQ)和代谢组学((1)H-NMR)图谱相结合,对之前的工作进行了扩展。通过对生物过程的富集分析和生物标志物筛选,对候选蛋白进行了分析。随后,使用 3Omics 网络工具来确定蛋白质与适当代谢物之间的关系。ELISA 测定和 IHC 方法用于验证蛋白质组学结果;von Willebrand 因子(vWF)蛋白可能是 ASMq 的“治疗窗口”和 ASS 的生物标志物。这项研究可能对 TUM 的标准化和现代化具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7529/4906522/f164604d26fc/srep27831-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验